Serum Calprotectin – a NET Product – as a Biomarker of Disease Activity in Patients with Systemic Lupus Erythematosus: A Single-Center Case-Control Study from Poland

Iwona Homa-Mlak; Marcin Mazurek; Aleksandra Majdan; Radosław Mlak; Maria Majdan; Teresa Mełecka-Massalska

doi:10.12659/MSM.936534

13 July 2022 : Clinical Research

Serum Calprotectin – a NET Product – as a Biomarker of Disease Activity in Patients with Systemic Lupus Erythematosus: A Single-Center Case-Control Study from Poland

Iwona Homa-Mlak^1ACDEF*, Marcin Mazurek^1BCEF, Aleksandra Majdan

^1DEF, Radosław Mlak^1ACDE, Maria Majdan

^2ADEF, Teresa Mełecka-Massalska^1ADEF

DOI: 10.12659/MSM.936534

Med Sci Monit 2022; 28:e936534

Authors information Article notes Copyright and License information

Background Material and Methods Results Discussion Conclusions References

Related articles Order reprints Share article Share by email

View HTML version

Figure 1 Receiver operating characteristic (ROC) curve – diagnostic utility of calprotectin concentration in detection of systemic lupus erythematosus (SLE).

Back to the Article

Serum Calprotectin – a NET Product – as a Biomarker of Disease Activity in Patients with Systemic Lupus Erythematosus: A Single-Center Case-Control Study from Poland

Your Privacy